What are the biopharmaceutical equipment

Abstract: Biopharmaceutical refers to the use of microbiology, biology, medicine, biochemistry and other research results, from organisms, biological tissues, cells, organs, body fluids, etc., the comprehensive use of microbiology, chemistry, biochemistry, biotechnology, pharmacy and other sciences of the principles and methods to manufacture a class of products for the prevention, treatment and diagnosis. What are the biopharmaceutical equipment? What is the prospect of the biopharmaceutical industry? Take a look. Biopharmaceutical machinery and equipment What are the biopharmaceutical equipment What are the biopharmaceutical equipment

What are the biopharmaceutical equipment

Biopharmaceutical laboratories, usually use shaker, bioreactor, fermenter, incubator, biochemical incubator, carbon dioxide incubator, autoclave, circulating cooled water machine, compressor, but also include cell crusher, high pressure homogenizer, freeze dryer Spray Dryer, Centrifugal Concentrator, Biochemical Analyzer, etc.

Biopharmaceutical industry analysis

Biopharmaceutical is the use of living organisms to produce drugs, such as the use of genetically modified corn to produce human antibodies, genetically modified bovine mammary glands to express human α1 antitrypsin. Biopharmaceutical industry has a bright future, half of the world's pharmaceuticals have been biosynthesis, it will be widely used in the treatment of cancer, AIDS, coronary heart disease, anemia, dysplasia, diabetes and many other diseases. The vast majority of antibiotics that have been applied in medicine come from microorganisms, such as erythromycin, jasmine, etc. Penicillin, streptomycin, gentamicin, etc. for injection. China's biotechnology industry engaged in research, development, production and operation of the number of people is only equivalent to the number of biotechnology industry in the U.S. 1/4. engaged in the research and development of biomedical products is a serious shortage of talent, has become a constraint on the development of China's biomedical industry bottleneck.

The development of the domestic biopharmaceutical industry is characterized by small scale, low concentration and rapid growth. China's biopharmaceutical industry sales, although a substantial increase but only and the United States biochemical company Amgen a sales close. Hualan Biological, Tiantan Biological, Kewa Biological, Shuanglu Pharmaceuticals, Daan Genetics five listed companies annual sales accounted for only about four percent of the market share. There is an imbalance in the production capacity structure of China's biopharmaceutical enterprises, high-end drug production capacity is insufficient, the phenomenon of low-end drug overcapacity. Such as China's vaccine production of more than half of the products are used for the prevention of polio, measles and other common diseases vaccine, no on the cutting-edge cancer, AIDS vaccine development, at present I within the biopharmaceutical industry enterprises of independent research and development capabilities of the product is relatively weak, to the imitation of the drug and the API-based, poor competitiveness. Our country has been approved for listing the original biological drugs only about five percent, the vast majority of generic drugs. Domestic biopharmaceutical industry in the R & D investment in only a small number of bio-pharmaceutical companies close to the international level, the vast majority of bio-pharmaceutical companies invested less in research and development.

Biopharmaceutical Prospect Analysis

Development Prospects

Biopharmaceutical technology, as a kind of high-tech, was born in the early 70's along with the invention and application of DNA recombination technology and lymphocyte hybridoma technology. Over the past thirty years, the rapid development of biopharmaceutical technology has opened up a broad prospect for the development of medical and pharmaceutical industries and greatly improved people's lives. Therefore, countries around the world have identified biopharmaceuticals as a key technology and emerging industry for the development of science and technology in the 21st century.

Biopharmaceutical specialty features that biopharmaceuticals have become one of the fastest growing industries both internationally and domestically, the 21st century is the century of biotechnology, and biopharmaceuticals have become a key focus for detecting China's high-tech development.

In the shadow of the global financial crisis, the emerging countries pharmaceutical market but the performance of the scenery this side of the good, China as one of the "BRIC", the biopharmaceutical market is also exceptionally bright. The National Development and Reform Commission to arrange for new central investment of 442 million yuan to support biopharmaceuticals, bio-breeding, biomedical engineering, high-tech industrialization of special projects and national bio-industrial base of public **** service conditions for the construction of special construction. This move for the future development of biopharmaceuticals injected a new impetus.

Although after years of development, China's biomedical industry has a good foundation, but compared with the world's advanced countries in the biomedical industry, China's biomedical industry there are still many gaps. The development of China's biomedical industry from scientific research to industrialization will be a difficult road. Governments at all levels, from national to local, have been increasing their efforts to support the development of the biomedical industry. By 2020, China will have basically achieved industrialization and built a perfect socialist market economic system and a more dynamic and open economic system. At the same time, the social security system will be relatively sound and a relatively complete modern medical and healthcare system will be formed. These two factors will create a huge market space and favorable development environment for the biomedical industry.

Outlook

Overall, the future of China's biopharmaceutical industry is full of hope and promising. Looking ahead, China's biopharmaceutical industry will continue to grow. In the coming period of time, China's biological and biochemical products industry will continue to show faster development trend.

Salary level: As medical engineers cover more fields, the employer's situation and each person's education and ability are different, so the salary of this career has great flexibility, the general college graduates monthly salary of about 3,000 yuan.

Occupational outlook: with the combination of biology, medicine and engineering technology, the prospect of comprehensive talents. This type of talent needs to have two skills: one is the development of new products, and the other is the operation of the instrument. Biomedical engineering field, biotechnology, bioinformatics, medical and health departments and other related units have a strong demand for this type of talent ......

Professional Characteristics

Professional Prospects Biotechnology drugs have been widely used in the treatment of cancer, AIDS, anemia, dysplasia, diabetes, heart failure, hemophilia, cystic fibrosis, and some rare genetic disorders. Many large pharmaceutical companies are faced with a large number of patents that are about to expire, while at the same time having a very short product pipeline, and are thus forced to look to life science companies for new drugs. New drug discovery technologies are making it cheaper, faster, and more accurate to find disease-specific drug targets.

Professional Prospects

China is the world's largest country in terms of population, however, the number of people engaged in biotechnology industry research and development of 17,000 people, the number of people engaged in the production and operation of 0.9 million people, equivalent to the United States biotechnology industry is only 1/4 of the number of people engaged in the biotechnology industry. engaged in the biomedical product research and development of talent is even more serious shortage of talent has become a constraint on China's development of the biomedical industry bottleneck.

It can be seen that the development of China's biomedical industry is in urgent need of a large number of pharmaceutical senior specialized technical personnel.